Martell Biosystems Seeks Investors to Develop Non-Invasive Breast Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Early-stage in vitro diagnostics company Martell Biosystems is seeking approximately $3 million in venture capital to help set up shop near the Mayo Clinic in downtown Rochester, Minn., to develop a non-invasive, DNA amplification-based blood test to diagnose breast and other types of cancer, according to a company official.

Martell also needs the funding to finalize a licensing agreement for the core technology with the University of Pennsylvania, where it was developed, Martell President and COO Phil Messina told GWDN recently.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.